Retrieve all available abstracts of the following 291 articles: HTML format
Single Articles
AIZEZI X, Silafu B, Ma Y, Wang Z, et al Analysis of IGFL2 Gene Expression and Prognostic Value in Bladder Cancer Based On
TCGA Database.
Asia Pac J Clin Oncol. 2025 May 29. doi: 10.1111/ajco.14191. PubMed Abstract available
QIU Y, Ruan H, Ji D, Cao N, et al NEURL1 acts as a candidate suppressor in bladder cancer by down-regulating PDE9A.
In Vitro Cell Dev Biol Anim. 2025 May 29. doi: 10.1007/s11626-025-01047. PubMed Abstract available
LIU Z, Chen Z, Yang H, Liu J, et al miR-944 inhibits malignant progression of bladder cancer through ATIC/AKT/FOXO3 A
axis mediated by SHMT1.
In Vitro Cell Dev Biol Anim. 2025 May 29. doi: 10.1007/s11626-025-01050. PubMed Abstract available
HUANG H, Shao H, Wang Y, Ge L, et al Disulfide bond-related gene signature development for bladder cancer prognosis
prediction and immune microenvironment characterization.
Sci Rep. 2025;15:18826. PubMed Abstract available
HUANG S, Jia K, Cui J, Duan J, et al Impact of pelvic lymph node dissection on survival outcomes in non-muscle
invasive bladder cancer: a multicenter retrospective study.
Sci Rep. 2025;15:18905. PubMed Abstract available
LI N, Wang X, Duan F, Wang X, et al Association of different treatment modalities for rectal cancer and second
primary urinary system neoplasms, findings from SEER.
Sci Rep. 2025;15:18782. PubMed Abstract available
ZHU A, Sher J, Li R, Ioseliani O, et al What motivates bladder cancer patients to be active? A qualitative study
assessing attitudes towards physical activity and digital health technologies.
Urol Oncol. 2025 May 28:S1078-1439(25)00176. PubMed Abstract available
HASSOUNEH Z, Noel ODV, Ji N, Kim ME, et al CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects
in bladder cancer.
Neoplasia. 2025;66:101187. PubMed Abstract available
SAVIN Z, Ben-David R, Durbhakula V, Gupta K, et al Does having an asymptomatic renal stone increase morbidity after radical
cystectomy?
World J Urol. 2025;43:336. PubMed Abstract available
KASSEM A, Assem A, Sharawy A, Ezz El Deen M, et al The Effect of Surgeon Experience on the Recurrence of Non-Muscle Invasive Bladder
Cancer (NMIBC), Following Transurethral Resection of the Bladder Tumor (TURBT): A
double Blinded Prospective Randomized Study.
Asian Pac J Cancer Prev. 2025;26:1767-1771. PubMed Abstract available
ADAN MM, Mao X, Ding L, Abdullahi KM, et al Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle
invasive bladder cancer: A meta-analysis with exploratory chemotherapy
comparisons.
Oncol Lett. 2025;30:348. PubMed Abstract available
ZHANG P, Zhang H, Yu W, Fan D, et al A lactate-related tSNE signature defines prognostic subtypes of bladder cancer
and reveals LINC01094-mediated VIM stabilization in metastasis and drug
resistance.
Front Immunol. 2025;16:1593523. PubMed Abstract available
WU F, Huang K, Yang J, Zhang L, et al Septicemia following sudden pituitary apoplexy after bladder tumor surgery: a
case report.
BMC Neurol. 2025;25:228. PubMed Abstract available
ZHENG Q ASO Author Reflections: Artificial Intelligence in Bladder Cancer-Transforming
Diagnosis and Treatment Paradigms.
Ann Surg Oncol. 2025 May 28. doi: 10.1245/s10434-025-17538. PubMed
GAO Y, Xu H, Zhao Q, Cai D, et al The key regulator circPDE3B promotes arsenic-induced bladder carcinogenesis by
affecting STAT3 and NF-kappaB stability.
Cell Biol Toxicol. 2025;41:91. PubMed Abstract available
GERSHMAN B, Ernandez J, Kaul S, Perez-Londono A, et al Associations of a claims-based frailty index with perioperative outcomes and
survival among older adults undergoing radical cystectomy for bladder cancer.
Urol Oncol. 2025 May 27:S1078-1439(25)00168. PubMed Abstract available
MARKERS D RETRACTION: Nesfatin-1/Nucleobindin-2 Is a Potent Prognostic Marker and Enhances
Cell Proliferation, Migration, and Invasion in Bladder Cancer.
Dis Markers. 2025;2025:9803765. PubMed Abstract available
ZHANG F, Li S Antibody-drug conjugates as game changers in bladder cancer: current progress and
future directions.
Front Immunol. 2025;16:1591191. PubMed Abstract available
HU W, Liang J, Luo J, Fan J, et al Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in
non-muscle invasive bladder cancer: a systematic review and meta-analysis.
Front Immunol. 2025;16:1578069. PubMed Abstract available
AHMAD A, Ranjan N, Babelay G, Dheeraj K, et al A Prospective Assessment of the Vesical Imaging Reporting and Data System in the
Diagnosis of Muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e83068. PubMed Abstract available
BERTAUX M, Luo C, Radulescu C, Beuzeboc P, et al Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of
Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients.
Pharmaceuticals (Basel). 2025;18:701. PubMed Abstract available
STURM S, Niegisch G, Windolf J, Suschek CV, et al Correction: Sturm et al. Exposure of Bladder Cancer Cells to Blue Light (lambda = 453
nm) in the Presence of Riboflavin Synergistically Enhances the Cytotoxic
Efficiency of Gemcitabine. Int. J. Mol. Sci. 2024, 25, 4868.
Int J Mol Sci. 2025;26:4790. PubMed Abstract available
RELVAS-SANTOS M, Ferreira D, Brandao A, Afonso LP, et al Glycomics and Glycoproteomics Reveal Distinct Oligomannose Carriers Across
Bladder Cancer Stages.
Int J Mol Sci. 2025;26:4891. PubMed Abstract available
YANG J, Wu W, Tang X Integration of Single-Cell and Bulk Transcriptome to Reveal an Endothelial
Transition Signature Predicting Bladder Cancer Prognosis.
Biology (Basel). 2025;14:486. PubMed Abstract available
CAMPISTOL M, Lozano F, Carrion A, Raventos CX, et al Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review.
Cancers (Basel). 2025;17:1714. PubMed Abstract available
ZHANG J, Jiang Z, Jin J, Kadeerhan G, et al Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer:
A Multidisciplinary Bioinformatics Approach.
Biomedicines. 2025;13:1203. PubMed Abstract available
LIU F, Li K, Zhu Q Targeting Metabolic Reprogramming in Bladder Cancer Immunotherapy: A Precision
Medicine Approach.
Biomedicines. 2025;13:1145. PubMed Abstract available
LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al Cancer-Specific Mortality of Partial Cystectomy Versus Radical Cystectomy in
T2N0M0 Urothelial Bladder Cancer.
Ann Surg Oncol. 2025 May 27. doi: 10.1245/s10434-025-17488. PubMed Abstract available
SWAMINATHAN M, Holt SK, Gore JL, Nyame YA, et al Association Between Rheumatoid Arthritis, Frailty Status, and Mortality in Older
Adults with Bladder Cancer.
Clin Genitourin Cancer. 2025 Apr 30:102369. doi: 10.1016/j.clgc.2025.102369. PubMed Abstract available
FURRIEL F, Ferreira H, Sampaio-Ribeiro G, Pereira M, et al Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of
anti-PD-L1 immunotherapy in bladder cancer.
Biomed Pharmacother. 2025;188:118188. PubMed Abstract available
SHUKLA CP, Jain NK, O'Donnell MA, Vachhani KV, et al Desmocollin-3 and Bladder Cancer.
Diseases. 2025;13:131. PubMed Abstract available
FAHEY CC, Clark-Garvey S, Porten S, Kamat AM, et al Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial
Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for
Bladder Cancer Care and Research Symposium.
Curr Oncol. 2025;32:278. PubMed Abstract available
YAMAMOTO A, Izutsu R, Seong H, Shimizu R, et al AMIGO2 expression at the invasive front of bladder cancer predicts
recurrence-free and overall survival after radical cystectomy.
Oncol Lett. 2025;30:339. PubMed Abstract available
YAJIMA S, Imasato N, Masuda H Novel neoadjuvant therapies for muscle-invasive bladder cancer: Systematic review
and meta-analysis.
BJUI Compass. 2025;6:e70031. PubMed Abstract available
QIN J, Liao K, Huang L, Qiu R, et al Proteome-driven transcriptomic dissection of EMT networks in bladder cancer based
on the VIM and CDH2 protein macromolecules influence: From molecular-protein
subtyping to therapeutic target prioritization.
Int J Biol Macromol. 2025;315. PubMed Abstract available
SHI Q, Geng J, Han L, Ji X, et al Engineered Salmonella Carrying siRNA-PD-1 Shrinks orthotopically implanted
Bladder Cancer in Rats.
J Drug Target. 2025 May 26:1-12. doi: 10.1080/1061186X.2025.2512619. PubMed Abstract available
MANOLITSIS I, Kapriniotis K, Katsimperis S, Angelopoulos P, et al The use of ctDNA for muscle-invasive bladder cancer before and after radical
cystectomy.
Expert Rev Anticancer Ther. 2025 May 26. doi: 10.1080/14737140.2025.2512036. PubMed Abstract available
TISSOT G, Gabriel PE, Dubuet U, Regnier S, et al Impact on oncological outcomes of detrusor muscle absence in pTaHG urothelial
carcinoma of the bladder? The end of the "jump" of the lamina propria layer myth.
World J Urol. 2025;43:324. PubMed Abstract available
LI N, Wang L, Yang Q, Li F, et al Identification and Evaluation of the Urinary Microbiota Associated With Bladder
Cancer.
Cancer Innov. 2025;4:e70012. PubMed Abstract available
LI P, Yang X, Liu Q, Zhang H, et al Bladder cancer biomarker analysis and drugtarget prediction based on
pyroptosis-related genes.
Discov Oncol. 2025;16:924. PubMed Abstract available
BDIOUI A, Akkari M, Krifa M, Souiden Y, et al Microsatellite instability and mismatch repair deficiency in bladder urothelial
carcinoma: a Tunisian single-center study.
J Egypt Natl Canc Inst. 2025;37:22. PubMed Abstract available
ESCANO MRJ, Vertosick EA, D'Souza N, Benfante N, et al Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Guerin
(BCG)-unresponsive non-muscle-invasive bladder cancer.
Urol Oncol. 2025 May 24:S1078-1439(25)00134. PubMed Abstract available
SAINI D, Chaudhary PK, Verma GK, Chaudhary JK, et al Molecular mechanistic approach to reveal decitabine's effect on DNMT gene
modulation and its inhibitory role in heavy metal-induced proliferation in
urinary bladder cancer cell line.
Toxicol In Vitro. 2025 May 23:106082. doi: 10.1016/j.tiv.2025.106082. PubMed Abstract available
YAPRAK BAYRAK B, Dogan HN, Teke K, Yuvak H, et al The role of tumor-infiltrating lymphocytes and depth of invasion in T1 bladder
cancer: a retrospective analysis.
BMC Urol. 2025;25:135. PubMed Abstract available
SONPAVDE GP Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in
Bladder Cancer: A Justified Standard.
Eur Urol Focus. 2025 May 23:S2405-4569(25)00121. PubMed Abstract available
KAYAR K, Kayar R, Karabay E, Ozdemir BB, et al Prognostic role of pathological substaging in high-grade pT1 bladder cancer
undergoing BCG therapy: Insights on recurrence and progression.
Urol Oncol. 2025 May 23:S1078-1439(25)00174. PubMed Abstract available
BLANC J, Carnot A, Barthelemy P, Casert V, et al Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder
cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.
J Immunother Cancer. 2025;13:e012045. PubMed Abstract available
ACHARD V, Abdel-Aty H, Santana VD, Bebek M, et al Combining Radiotherapy with Immune Checkpoint Inhibitors for the Management of
Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review from the Y-ECI
ROSC EORTC group.
Pract Radiat Oncol. 2025 May 22:S1879-8500(25)00147. PubMed Abstract available
LIU QF, Hao P, Wang T A meta-analytic appraisal of robotic-assisted cystectomy outcomes in the elderly
octogenarian population.
J Robot Surg. 2025;19:232. PubMed Abstract available
DENG X, Zheng R, Tan X, Yao K, et al HER2 prognostic values in non-muscle-invasive bladder cancer: a step towards
personalized treatment for BCG instillation.
Discov Oncol. 2025;16:891. PubMed Abstract available
XU H, Li J, Peng S, Bai Y, et al From exposure to innovation: decoding aromatic amines' role in bladder cancer
mechanisms.
Discov Oncol. 2025;16:888. PubMed Abstract available
DANELLI L Sex-specific gut microbiota and neutrophil senescence in bladder cancer.
Nat Cancer. 2025;6:738. PubMed
SHARMA P, Sharma B, Yadav DP, Thakral D, et al Bladder lesion detection using EfficientNet and hybrid attention transformer
through attention transformation.
Sci Rep. 2025;15:18042. PubMed Abstract available
H B, Meshram N, Thomas T, C H H, et al Metanephrine normal, DOTATATE negative paraganglioma of the urinary bladder.
BMJ Case Rep. 2025;18:e266048. PubMed Abstract available
WONG BNX, Francis M, El-Khoury HJ, Woon D, et al Infrapubic Foley catheter balloon tamponade for retropubic venous haemorrhage
during radical cystoprostatectomy and urethrectomy.
BMJ Case Rep. 2025;18:e265030. PubMed Abstract available
DENG P, Zhong C, He P, Liu Q, et al Uncovering citron kinase as a key biomarker for predicting outcomes and therapy
efficacy in non-muscle-invasive bladder cancer.
Gene. 2025 May 21:149590. doi: 10.1016/j.gene.2025.149590. PubMed Abstract available
KORENTZELOS D, Diamantopoulos L, Mohebnasab M, Dhir R, et al Plasmacytoid urothelial carcinoma of the urinary bladder: A single institution
experience with focus on next-generation sequencing (NGS) and PD-L1
immunohistochemistry.
Hum Pathol. 2025;158:105788. PubMed Abstract available
TUCHENHAGEN K, Vag T, Kriegmair MC [mpMRI of the Urinary Bladder: Significance and Clinical Use].
Aktuelle Urol. 2025;56:248-257. PubMed Abstract available
RICHTERS A, Suelmann B, Franken M, Mehra N, et al Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer:
comparison between patients from a Dutch nationwide cohort and KEYNOTE-045.
Cancer Treat Res Commun. 2025;43:100931. PubMed Abstract available
SANGUEDOLCE F, Cormio A, Zanelli M, Palicelli A, et al Diagnostic workout of glandular malignant lesions of the bladder according to the
5th WHO classification.
Crit Rev Clin Lab Sci. 2025;62:301-312. PubMed Abstract available
LEE D, Jeon KH, Jung J, Han K, et al Urological cancer risk in patients with rheumatoid arthritis compared to matched
controls: a nationwide cohort study.
Rheumatology (Oxford). 2025;64:3458-3467. PubMed Abstract available
NIENTIEDT M, Waldbillig F [Bimodal and multimodal endoscopy of the urinary bladder in diagnosis and
treatment].
Aktuelle Urol. 2025;56:242-247. PubMed Abstract available
HARANO T, Ikeda M, Hirano S, Shimura S, et al Safety and Efficacy of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin with Pegfilgrastim in Japanese Patients with Advanced or Metastatic
Urothelial Carcinoma.
Chemotherapy. 2025;70:85-91. PubMed Abstract available
WANG Y, Strzepek TJ, Costello DM, Crowley PA, et al Cytologic Assessment of the Supernatants of Formalin Solution Following
Histologic Examination of Transurethral Biopsy/Resection Specimens: Potential
Detection of Denuded Urothelial Cancer Cells.
Arch Pathol Lab Med. 2025;149:573-577. PubMed Abstract available
ZHANG J, Yang H, Zhang X, Chen J, et al Prognostic significance of copper metabolism-related genes as risk markers in
bladder urothelial carcinoma.
Nucleosides Nucleotides Nucleic Acids. 2025;44:598-616. PubMed Abstract available
DING Q, Zhu H, Fan B, Wang L, et al Chromosomal instability by low-coverage whole-genome sequencing assay predicts
prognosis in bladder cancer patients underwent radical cystectomy.
BMC Med Genomics. 2025;18:103. PubMed Abstract available
YANG L, Hu X, Ye X, Zhang W, et al Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in
Patients with Bladder Cancer: A Systematic Review and Meta-analysis.
Ann Surg Oncol. 2025 Jun 5. doi: 10.1245/s10434-025-17600. PubMed Abstract available
CHI Q, Teng H, Zhao Y, Wang X, et al Design and synthesis of 3,4-seco-lupane triterpene-tryptamine derivatives and
revealing their anti-bladder cancer mechanisms by combining TCGA and
transcriptomic approaches.
Sci Rep. 2025;15:19723. PubMed Abstract available
MUROFUSHI R, Ikarashi D, Nozaki Y, Toyoshima M, et al [A Case of Cut-to-the-light Incision for Ureteroileal Anastomotic Obstruction
after Robot-Assisted Radical Cystectomy and Ileal Conduit].
Hinyokika Kiyo. 2025;71:155-158. PubMed Abstract available
KIRUBA B, Narayan PSA, Raj B, Raj SR, et al Intervention of machine learning in bladder cancer research using multi-omics
datasets: systematic review on biomarker identification.
Discov Oncol. 2025;16:1010. PubMed Abstract available
PATTOU M, Peyrottes A, Neuzillet Y, Lebret T, et al Outpatient transurethral resection of bladder tumors: A systematic review of
oncologic and safety outcomes.
World J Urol. 2025;43:359. PubMed Abstract available
NIKKHAH O, Einollahi B, Asadi M, Heiat M, et al Gene network changes after exposure to nanoliposomes containing antisense miR-21
and miR-373 in bladder cancer Cells: An in vitro model study.
Biochem Biophys Rep. 2025;42:102041. PubMed Abstract available
HU J, Yan L, Liu J, Chen M, et al Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC)
combined immunotherapy in patients with muscle-invasive bladder cancer: A
multi-center real-world study.
Imeta. 2025;4:e70033. PubMed Abstract available
LIU P, Li X, Li J, Li Z, et al Pediatric papillary urothelial neoplasm: 18-year single-center experience in
diagnosis and treatment.
BMC Urol. 2025;25:148. PubMed Abstract available
FAN B, Zhang L, Cui H, Bai S, et al Development of a machine learning-based model to predict urethral recurrence
following radical cystectomy: a multicentre retrospective study and updated
meta-analysis.
Sci Rep. 2025;15:19573. PubMed Abstract available
LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al ASO Visual Abstract: Cancer-Specific Mortality of Partial Cystectomy Versus
Radical Cystectomy in T2N0M0 Urothelial Bladder Cancer.
Ann Surg Oncol. 2025 Jun 4. doi: 10.1245/s10434-025-17637. PubMed
BARNABA D, Franzese Canonico M, Helmer-Citterich M, Gandellini P, et al LEADR, a p63 target, dampens interferon signalling in bladder cancer.
Cell Death Discov. 2025;11:264. PubMed Abstract available
LEE J, Choi US, Kwon M, Yoon H, et al Methodological evaluation of ultrasound-guided modified traumatic catheterization
in dogs with suspected urothelial carcinoma.
J Vet Sci. 2025;26:e32. PubMed Abstract available
XIAO Y, Ju L, Wang G, Jin W, et al Elucidating the pathogenesis of bladder cancer through single-cell chromatin
accessibility and DNA methylation analysis.
Genes Dis. 2025;12:101578. PubMed
LI Y, Huang S, Ju W, Lu D, et al Deciphering riddles in molecular subtyping of bladder cancer.
Asian J Urol. 2025;12:217-231. PubMed Abstract available
WANG Y, Bhandary P, Griffin K, Moore JH, et al Integrative multi-omics study identifies sex-specific molecular signatures and
immune modulation in bladder cancer.
Front Bioinform. 2025;5:1575790. PubMed Abstract available
PHAM YT, Wang R, Yuan JM, Luu HN, et al Low-carbohydrate diet score and risk of bladder cancer: Findings from a
prospective cohort study.
BJUI Compass. 2025;6:e70033. PubMed Abstract available
WANG Y, Wang H, Li N, Wu S, et al Unsupervised learning-based quantitative analysis of CT intratumoral subregions
predicts risk stratification of bladder cancer patients.
BMC Med. 2025;23:328. PubMed Abstract available
WU Z, Qu C, Liang G, Sun R, et al Double-J stenting during TURBT increases risk of metachronous upper tract
urothelial carcinoma.
BMC Urol. 2025;25:146. PubMed Abstract available
FINOCCHIARO A, Tylecki A, Stephens A, Vigano S, et al Socioeconomic disparities and MIBC survival outcome-An analysis of a statewide
cohort.
World J Urol. 2025;43:349. PubMed Abstract available
HU J, Fu X, Zhang Y, Zhang M, et al Hyperspectral Imaging for Predicting Bladder Cancer Grading: A Novel Diagnostic
Approach.
J Biophotonics. 2025 Jun 2:e202500161. doi: 10.1002/jbio.202500161. PubMed Abstract available
DRANOVE D When A Health Economist Becomes A Cancer Patient.
Health Aff (Millwood). 2025;44:761-765. PubMed Abstract available
BARNS M, Powell E, Kuan M Tuberculosis epididymitis presenting as an acute scrotum in a 65 year-old man
undergoing BCG treatment for bladder cancer.
Urol Case Rep. 2025;61:103009. PubMed Abstract available
CUI S, Liang B, Liu Y Unveiling Oncogenic Power of WAVE1 in Bladder Cancer Progression.
Biochemistry (Mosc). 2025;90:534-543. PubMed Abstract available
AHMED A, Nasir S, Jalbani IK, Qadri A, et al Primary urothelial carcinoma of an ileal conduit; six decades after childhood
bladder exstrophy surgery: a rare and late complication.
World J Surg Oncol. 2025;23:211. PubMed Abstract available
SU X, Chen F, Shi Z, Tao Y, et al Global insight of early-onset genitourinary cancers in adolescents and adults
from 1990 to 2021: temporal trends and health inequalities analyses.
World J Surg Oncol. 2025;23:208. PubMed Abstract available
SHORE ND, Powles TB, Bedke J, Galsky MD, et al Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer:
the randomized phase 3 CREST trial.
Nat Med. 2025 May 31. doi: 10.1038/s41591-025-03738. PubMed Abstract available
LIU K, Jiao B, Zhang G, Gan Z, et al Self-enhanced ROS-responsive camptothecin prodrug nanoparticles elicit safe and
efficient intravesical instillation therapy of bladder cancer.
J Control Release. 2025;384:113905. PubMed Abstract available
WANG B, He C, Li Y, Jiang Y, et al Aminopeptidase N-Triggered Electron Rearrangement of Fluorescein for Covalent
Fluorescent Labeling and Image-Guided Orthotopic Bladder Cancer Resection.
Anal Chem. 2025 May 31. doi: 10.1021/acs.analchem.5c02393. PubMed Abstract available
MA M, Wang S, Wang K, Jiang B, et al CXCL12 links bladder cancer and diabetes as a potential biomarker.
Sci Rep. 2025;15:19017. PubMed Abstract available
ZUO J, Chen J, Wang J Reassessing the role of the gut microbiome in bladder cancer: A review of
methodological approaches and future research directions.
Urol Oncol. 2025;43:436-437. PubMed
FINOCCHIARO A, Tylecki A, Vigano S, Bertini A, et al Socioeconomic disparities and bladder cancer stage at diagnosis: a statewide
cohort analysis.
JNCI Cancer Spectr. 2025 May 30:pkaf054. doi: 10.1093. PubMed Abstract available
CARNEIRO BA, Gbolahan OB, Abdul Razak AA, Hilton JF, et al First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody
AZD8853 in Patients with Advanced/Metastatic Solid Tumors.
Cancer Res Commun. 2025;5:896-905. PubMed Abstract available
DE ANGELIS M, Siech C, Jannello LMI, Bello FD, et al Sex-related differences in response to neoadjuvant and adjuvant chemotherapy in
urothelial carcinoma of urinary bladder treated with radical cystectomy.
Urol Oncol. 2025;43:442. PubMed Abstract available
TAVELLI JP, Chung R, Bai K, Gorroochurn P, et al The impact of age on BCG treatment response.
Urol Oncol. 2025;43:440. PubMed Abstract available
YONESE I, Yasuda Y, Takemura K, Toide M, et al Impact of IRAES on the outcomes of pembrolizumab therapy in patients with MUC: A
comprehensive analysis of severity and the type and number of affected organs.
Urol Oncol. 2025;43:441. PubMed Abstract available
PICHLER R, van Creij NCH, Subiela JD, Cimadamore A, et al Biological and therapeutic implications of FGFR alterations in urothelial cancer:
A systematic review from non-muscle-invasive to metastatic disease.
Actas Urol Esp (Engl Ed). 2025;49:501719. PubMed Abstract available
ALBERS ACOSTA E, Pelari-Mici L, Celada Luis G, Velasco Balanza C, et al The impact of a multidisciplinary approach on treatment decisions and outcomes in
urothelial carcinoma: A systematic review.
Actas Urol Esp (Engl Ed). 2025;49:501718. PubMed Abstract available
PALLAUF M, Bronimann S, Rezaee ME, Kohn TP, et al Metformin intake and risk of metabolic acidosis after radical cystectomy with
urinary diversion: A comparative study using data from the TriNetX research
network.
Urol Oncol. 2025;43:441. PubMed Abstract available
MA X, Pan C, Xu A, Guo X, et al Benign Glomus Tumor of the Urinary Bladder: A Case Report and Literature Review.
Int J Surg Pathol. 2025;33:1082-1088. PubMed Abstract available
RIEGER C, Schluchtermann J, Lehmann M, Storz E, et al Cost-effectiveness Analysis in the New Era of Treatment Strategies in Metastatic
Urothelial Carcinoma Based on Checkmate-901 and EV302/Keynote-A39.
Eur Urol Oncol. 2025;8:681-688. PubMed Abstract available
XING T, Wang Z, Hao X, Mu J, et al Copper Nanoparticles Green-Formulated by Curcuma longa Extract Induce Apoptosis
via P53 and STAT3 Signaling Pathways in Bladder Carcinoma Cell.
Biol Trace Elem Res. 2025;203:2606-2618. PubMed Abstract available
RIZKALLA CN, Srinivas S, Sangoi AR Incidence and Pitfalls of Adipose Tissue Encountered in Urinary Bladder
Biopsy/Transurethral Resection Specimens.
Int J Surg Pathol. 2025;33:596-604. PubMed Abstract available
LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al Cancer-Specific Survival of Trimodal Therapy Versus Radical Cystectomy in T2N0M0
Non-Urothelial Bladder Cancer.
J Surg Oncol. 2025 Jun 13. doi: 10.1002/jso.70014. PubMed Abstract available
ZHANG Z, Zhong J, Iqbal MS, Zeng Z, et al A comprehensive risk model of disulfidoptosis-related lncRNAs predicts prognosis
and therapeutic implications in bladder cancer.
Biochem Biophys Rep. 2025;42:102060. PubMed Abstract available
YU Q, Li B, Lin H, Sun C, et al Smoking-related bladder cancer burden from 1990 to 2021: An age-period-cohort
analysis of the global burden of disease study.
Tob Induc Dis. 2025;23. PubMed Abstract available
MAEDA A, Tobu S, Kawasaki M, Kakinoki H, et al Prospective Analysis of Residual Urine Volume and Its Association With
Intravesical Recurrence in Patients With Non-Muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e84023. PubMed Abstract available
IVANOV R, Afonnikov D, Matushkin Y, Lashin S, et al Evolutionary Transcriptomics of Cancer Development.
Int J Mol Sci. 2025;26:5041. PubMed Abstract available
SZYMANSKA B, Malkiewicz B, Dembowski J, Piwowar A, et al Usability Evaluation of Urinary HAI-1, STMN-1 and TN-C in the Diagnosis of
Bladder Cancer.
J Clin Med. 2025;14:3664. PubMed Abstract available
ZHANGA Y, Wang X, Li J, Zhang P, et al Global clinical trial landscape and therapeutic trends in bladder cancer: a
systematic analysis.
Int J Surg. 2025 Jun 12. doi: 10.1097/JS9.0000000000002662. PubMed Abstract available
LU DJ, Wang HR, Xu YS, Huang HB, et al Homeobox C6 plays an oncogenic role in bladder cancer.
World J Clin Oncol. 2025;16:103830. PubMed Abstract available
KATARI V, Dalal K, Kondapalli N, Paruchuri S, et al TRPV4 Channels Mediate Bladder Cancer Cell Proliferation, Migration and
Chemoresistance.
bioRxiv [Preprint]. 2025 Jun 7:2025.06.05.657842. doi: 10.1101/2025.06.05.657842 PubMed Abstract available
KWOK KHM, Abbadi A, Cote S, Baculea S, et al Characterization of treatment patterns and outcomes in muscle-invasive bladder
cancer patients in Sweden.
Scand J Urol. 2025;60:108-114. PubMed Abstract available
GAO H, Wong SQR, Subel E, Huang YH, et al Caspase-1-dependent pyroptosis converts alphaSMA(+) CAFs into collagen-III(high)
iCAFs to fuel chemoresistant cancer stem cells.
Sci Adv. 2025;11:eadt8697. PubMed Abstract available
ARORA A, Godse S, Pal M, Misra A, et al Real-world oncological and toxicity outcomes with the Moscow strain of
intravesical BCG for non-muscle invasive bladder cancer-Implications for global
shortage.
BJUI Compass. 2025;6:e70034. PubMed Abstract available
MARKERS D RETRACTION: KIF5A Promotes Bladder Cancer Proliferation In Vitro and In Vivo.
Dis Markers. 2025;2025:9767430. PubMed Abstract available
HAMMAD AA, Ezzat O, Filicevas A, Hammad SA, et al Enhancing bladder cancer awareness and knowledge through multifaceted community
engagement in Egypt: a cross-sectional study.
Ecancermedicalscience. 2025;19:1886. PubMed Abstract available
CAO X, Gao D, Zhang S, Yu X, et al Cytotoxic effect of bladder cancer oncolytic virus on bladder cancer stem-like
cells via pyroptosis pathway.
Technol Health Care. 2025 Jun 11:9287329251349081. PubMed Abstract available
MENOLD HS, Gruene B, Koenig J, Lenhart M, et al Impact of transurethral resection of bladder tumors on sexual function and
quality of life using ePROMs in patients with bladder cancer- a prospective
cohort study.
World J Urol. 2025;43:370. PubMed Abstract available
ZHENG F, Li S, Xiong S, Li Z, et al Loss of RNF41 promotes bladder cancer metastasis through increasing NUDC
stability to enhance tubulin polymerization.
Cell Death Dis. 2025;16:443. PubMed Abstract available
BASU M, Xiao JF, Kailasam Mani SK, Qu F, et al Genes driving three-dimensional growth of immortalized cells and cancer.
Cell Death Dis. 2025;16:442. PubMed Abstract available
KAILAVASAN M, Martini A, Bruins M, Carrion A, et al A Systematic Review and Meta-analysis on Perioperative Stenting/Dwell Time and
Postoperative Outcomes in Patients Undergoing Radical Cystectomy and Urinary
Diversion for Bladder Cancer.
Eur Urol Focus. 2025 Jun 9:S2405-4569(25)00154-3. doi: 10.1016/j.euf.2025. PubMed Abstract available
DE JONG JJ, Black PC, Dyrskjot L, Gibb EA, et al Long Noncoding RNAs Identify a Subgroup of Patients with Low-grade
Non-muscle-invasive Bladder Cancer with Less Favorable Outcomes.
Eur Urol Oncol. 2025 Jun 9:S2588-9311(25)00151-8. doi: 10.1016/j.euo.2025. PubMed Abstract available
SAHAY S, Trehan D, Kumari R, Sharma J, et al Anti-Cancer Role of Ellagic Acid by Modulating the Altered PI3K/PTEN/Akt Pathway
in Bladder Cancer.
J Environ Pathol Toxicol Oncol. 2025;44:57-69. PubMed Abstract available
ZHANG J, Zhang C, Zang R, Chen W, et al Targeting MAN1B1 potently enhances bladder cancer antitumor immunity via
deglycosylation of CD47.
Cancer Commun (Lond). 2025 Jun 10. doi: 10.1002/cac2.70040. PubMed Abstract available
YANG W, Zha J, Tang Y, Wang K, et al Bladder Cancer Growth is Inhibited by Upregulating CircFUT8 through the
METTL14/FMR1 Signaling Pathway.
Cell Biochem Biophys. 2025 Jun 10. doi: 10.1007/s12013-025-01794. PubMed Abstract available
WANG Z, Huang D, Li S, Ke L, et al Role of tumor mutational burden in patients with urothelial carcinoma treated
with immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2025;16:1592761. PubMed Abstract available
ZHENG B, Chen Z, Sun L, Quan J, et al Intravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In
Murine Model.
Int J Nanomedicine. 2025;20:7169-7183. PubMed Abstract available
CHEN R, He L, Huang Z, Sun J, et al Causal relationship between the plasma lipidome and urological cancers: A
two-sample Mendelian randomization study.
Medicine (Baltimore). 2025;104:e42577. PubMed Abstract available
LIN F, Yang K, Luo T, Chen T, et al Causal association between blood and urine biomarkers, immune cells, and bladder
cancer: A Mendelian randomization and mediation analysis.
Medicine (Baltimore). 2025;104:e42814. PubMed Abstract available
BARRAGAN-CARRILLO R, Ebrahimi H, John WS, Lucht S, et al Clinical Outcomes in Patients With Muscle-Invasive Urothelial Carcinoma Treated
With Nivolumab.
JAMA Netw Open. 2025;8:e2514427. PubMed Abstract available
RODRIGUES T, Candido P, Maluf FC, ROMaO P, et al Is miR-10a a tumor suppressor that modulates proliferation and invasion in
high-grade bladder cancer?
Oncol Res. 2025;33:1377-1382. PubMed Abstract available
ELAHI NAJAFI MA, Matsukawa T, Miyamoto H Recent advances in understanding the role of sex hormone receptors in urothelial
cancer.
Oncol Res. 2025;33:1255-1270. PubMed Abstract available
SABOYA L, Buosi K, Silva T, Candido E, et al Intradermal priming to intravesical Bacillus Calmette-Guerin in non-muscle
invasive bladder cancer: A translational research and phase I clinical trial.
Oncol Res. 2025;33:1495-1503. PubMed Abstract available
ZHANG Y, Li Z, Shao X, Jiang S, et al Inflammation as a key mediator: linking triglyceride-glucose index to prognosis
in non-muscle-invasive bladder cancer.
Front Oncol. 2025;15:1545985. PubMed Abstract available
QI L, Liu C, Zhang Y, Zhang Z, et al Correction: Qi et al. Development of Mitomycin C-Loaded Nanoparticles Prepared
Using the Micellar Assembly Driven by the Combined Effect of Hydrogen Bonding and
pi-pi Stacking and Its Therapeutic Application in Bladder Cancer. Pharmaceutics
2021, 13,
Pharmaceutics. 2025;17:733. PubMed Abstract available
JOFFE BI, Christin JR, Le Coz C, Gorroochurn P, et al Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in
patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic
correlations.
Urol Oncol. 2025 Jun 7:S1078-1439(25)00207-8. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
KANUMUAMBIDI JT, Rosales RR, Venkatesh A, Metzner T, et al Sex-based differences in genetic alterations and immune checkpoint inhibitor
response in urothelial bladder cancer.
Urol Oncol. 2025 Jun 6:S1078-1439(25)00204-2. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
KASPERCZYK E, Lesicka M, Reszka E Bladder cancer risk in aluminum production workers: A systematic review.
Actas Urol Esp (Engl Ed). 2025 Jun 5:501789. doi: 10.1016/j.acuroe.2025.501789. PubMed Abstract available
LI C, Lin Y, Zheng H, Zeng H, et al Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer.
Cancer Immunol Immunother. 2025;74:240. PubMed Abstract available
DENG W, Chen Y, Bai Y, Shang H, et al Genetically engineered T cell membrane-camouflaged nanoparticles triggered
cuproptosis for synergistic bladder cancer photothermal-immunotherapy.
J Nanobiotechnology. 2025;23:425. PubMed Abstract available
YU W, Yao D, Ma X, Hou J, et al A novel efferocytosis-related gene signature for predicting prognosis and
therapeutic response in bladder cancer.
Sci Rep. 2025;15:19912. PubMed Abstract available
NUSBAUM DJ, Shi Z, Ashworth A, Tran H, et al A polygenic risk score is associated with risk of bladder cancer and earlier age
of diagnosis, independent of lifestyle factors.
Urol Oncol. 2025 Jun 5:S1078-1439(25)00180-2. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
LI HZ, Zhu J, Weng GJ, Li JJ, et al AgAu@Ag core-shell triangular nanonet jointed with composite SERS enhanced
substrate for capturing and sensing urine biomarkers FGFR3 and NMP22.
Biosens Bioelectron. 2025;286:117635. PubMed Abstract available
SIDDIQUE F, Sharif N, Salam A, Saeed S, et al Expression of TIM-3 in transitional cell carcinoma: A comparative study of tissue
and serum levels.
Pathol Res Pract. 2025;271:156031. PubMed Abstract available
MERCADER C, Lopez R, Ferrer L, Calderon R, et al FGFR3 immunohistochemistry as a surrogate biomarker for FGFR3 alterations in
urothelial carcinoma.
Pathol Res Pract. 2025;271:156028. PubMed Abstract available
SHEN Y, Zheng L, Zhao J, Wang Y, et al Molecular profile of micropapillary urothelial carcinoma of the urinary bladder:
An analysis of 99 cases by next-generation sequencing.
Hum Pathol. 2025;159:105812. PubMed Abstract available
METWALLY S, Smialek-Bartyzel J, Pabijan J, Lekka M, et al Structural and Mechanical Characterization of Collagen-Hyaluronan Hydrogels Used
to Study Cancer Cell Invasion through the Bladder Wall.
ACS Biomater Sci Eng. 2025;11:3443-3454. PubMed Abstract available
LI A, Wu M, Xie O, Xiang H, et al Economic evaluation of Erdafitinib as a second-line treatment for advanced
metastatic urothelial carcinoma: real-world data from the USA and prospective
analysis from China.
Future Oncol. 2025;21:1919-1927. PubMed Abstract available
SEN A, Choudhary N, Goyal B, Gupta A, et al Expression of inflammatory proteins STAT & NFkB for phenotypic diagnosis of gall
bladder cancer: A pilot study.
Indian J Med Res. 2025;161:414-419. PubMed Abstract available
CARRERAS G, Possenti I, Malevolti MC, Gorini G, et al Second-hand smoke and bladder cancer risk among nonsmokers: a systematic review
and a meta-analysis.
Eur J Cancer Prev. 2025 Jun 18. doi: 10.1097/CEJ.0000000000000979. PubMed Abstract available
CHEN X, Lu JL, Li H, Liu GY, et al Resveratrol Induces Oxidative Stress and Downregulates GPX4 and xCT to Activate
the Ferroptosis Pathway for Anti-Bladder Cancer Organoids.
J Cancer. 2025;16:2613-2625. PubMed Abstract available
GU J, Shi ZD, Pang K, Hao L, et al Retinoic acid metabolism related gene CYP26B1 promotes tumor stemness and tumor
microenvironment remodeling in bladder cancer.
J Cancer. 2025;16:2476-2491. PubMed Abstract available
WANG Z, Mao J, Zhang Y, Yang W, et al Pan-cancer analysis reveals the potential role of DHCR24 in bladder cancer via
interactions with HRAS to facilitate cholesterol synthesis.
Oncol Lett. 2025;30:385. PubMed Abstract available
PAGANO I, Zhang Z, Luu M, Tikhonenkov S, et al Performance of the Oncuria-Detect bladder cancer test for evaluating patients
presenting with haematuria: results from a real-world clinical setting.
J Transl Med. 2025;23:680. PubMed Abstract available
DAI YN, Yu EY, Zeegers MP, Wesselius A, et al The association between diet and bladder cancer risk: a two-sample mendelian
randomization.
Eur J Nutr. 2025;64:223. PubMed Abstract available
PENG W, Li X, Wei S, Liu W, et al Machine Learning Characterization of Immunometabolism in the Tumor
Microenvironment and Immunotherapy Responses in Bladder Cancer.
J Immunother. 2025 Jun 18. doi: 10.1097/CJI.0000000000000568. PubMed Abstract available
ZHANG C, Liu S, Zhang J, Lu J, et al A Multifunctional Fe-EGCG@RSL3 Nanomedicine Synergizes Ferroptosis Induction and
Tumor Microenvironment Remodeling for Enhanced Bladder Cancer Immunotherapy.
Research (Wash D C). 2025;8:0735. PubMed Abstract available
FORD S, Hamilton ZA Variant histology muscle invasive bladder cancer should not preclude neoadjuvant
chemotherapy before cystectomy.
Transl Androl Urol. 2025;14:1187-1189. PubMed
CHEN S, Xu R, Cheng Y, Wu J, et al Clinical outcomes of modified partial cystectomy in muscle-invasive bladder
cancer: balancing tumor control and quality of life.
Transl Androl Urol. 2025;14:1444-1455. PubMed Abstract available
TASHIRO K, Urabe F, Kimura T Neoadjuvant chemotherapy for muscle-invasive bladder cancer with variant
histology and/or divergent differentiation.
Transl Androl Urol. 2025;14:1155-1157. PubMed
WANG Z, Zhou Z, Yang S, Li Z, et al Pathway-based cancer transcriptome deciphers a high-resolution intrinsic
heterogeneity within bladder cancer classification.
J Transl Med. 2025;23:666. PubMed Abstract available
LIANG J, Guo S, Wang Y, Cao Q, et al LINC00525 drives aggressive phenotypes in bladder cancer via YAP
stabilization-mediated transcriptional activation.
Cancer Cell Int. 2025;25:214. PubMed Abstract available
YANG H, Song H, Yip E, Gilpatrick T, et al Bladder cancer variants share aggressive features including a CA125+ cell state
and targetable TM4SF1 expression.
Nat Commun. 2025;16:5312. PubMed Abstract available
NIHAL A, Bacon P, Pei S Enfortumab vedotin-induced widespread vesiculobullous eruption mimicking
disseminated herpetic infection in a patient with metastatic urothelial
carcinoma.
Dermatol Online J. 2024;30. PubMed Abstract available
ZHAO Y, Zhang E, Wang Y, Zheng J, et al Assessment of atypical cells in detecting bladder cancer in female patients.
Clin Chem Lab Med. 2025 Jun 18. doi: 10.1515/cclm-2025-0268. PubMed Abstract available
KARAM EA, Celine YC, Prince G, Attieh F, et al Optimizing enfortumab vedotin plus pembrolizumab therapy.
Oncotarget. 2025;16:481-494. PubMed Abstract available
XIAOLONG H, Min D, Sizhou Z, Daorong H, et al Prognostic analysis of bladder cancer with neddylation-related genes.
Hereditas. 2025;162:105. PubMed Abstract available
CHEN Y, Luo F, Li J, Zhang T, et al Neoadjuvant Radiotherapy Combined with Transurethral Photoselective Vaporization
of Bladder Tumors and Postoperative Adjuvant Radiotherapy and Chemotherapy for T3
Muscle-Invasive Bladder Cancer: A Retrospective Case Series Study.
Photobiomodul Photomed Laser Surg. 2025 Jun 16. doi: 10.1089/photob.2024.0150. PubMed Abstract available
RODRIGUEZ PENARANDA N, Di Bello F, Marmiroli A, Falkenbach F, et al Effect of sex on adverse in-hospital outcomes after radical cystectomy according
to urinary diversion type.
World J Urol. 2025;43:375. PubMed Abstract available
WONG CH, Ko IC, Leung DK, Siu B, et al The importance of maximal TURBT in trimodality therapy for muscle-invasive
bladder cancer (MIBC).
Bladder Cancer. 2025;11:23523735251346569. PubMed Abstract available
LIU B, Gong S, Chen Y, Xiao B, et al Impact of immediate intravesical therapy on non-muscle invasive bladder cancer
with risk factors analysis for recurrence.
Am J Cancer Res. 2025;15:2275-2284. PubMed Abstract available
SONG R, Chen X, Zhang Z, Wang H, et al Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder
cancer treatment.
RSC Adv. 2025;15:20183-20191. PubMed Abstract available
JIA J, Wu G, Zhang H, Wang F, et al Magnetic-Driven Hydrogel Robots Loaded with Mitomycin for Active Therapy of
Bladder Cancer.
ACS Appl Mater Interfaces. 2025 Jun 16. doi: 10.1021/acsami.5c03787. PubMed Abstract available
MOSCHINI M, Rosiello G, Gandaglia G, Briganti A, et al Re: Alexandra Masson-Lecomte, Guillaume Grisay, Julien Van Damme, et al.
Challenges in Defining Clinical Complete Response to Systemic Therapy in
Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project. Eur
Urol Oncol. In press. http
Eur Urol Focus. 2025 Jun 14:S2405-4569(25)00161. PubMed
WANG Y, Zhou H, Tang Z, He Z, et al Smoking and bladder cancer: insights into pathogenesis and public health
implications from a bibliometric analysis (1999-2023).
Subst Abuse Treat Prev Policy. 2025;20:25. PubMed Abstract available
PENARANDA NR, de Angelis M, Siech C, Di Bello F, et al ASO Visual Abstract: Perioperative Complications and In-Hospital Mortality after
Cystectomy for Non-Bladder Cancer Conditions versus Radical Cystectomy for
Bladder Cancer.
Ann Surg Oncol. 2025 Jun 14. doi: 10.1245/s10434-025-17629. PubMed
WANG B, Davis LE, Weight CJ, Abouassaly R, et al Real-World Experience with a Commercial Circulating Tumor DNA Assay in
Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 Jun 13:S2588-9311(25)00165. PubMed Abstract available
KUMAR VELDI VD, Sah R Comment on "Oncological outcomes of patients with node positive disease following
neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder
cancer: A multicenter observational study of the EAU Young Academic Urologists
(YAU) urotheli
Actas Urol Esp (Engl Ed). 2025 Jun 12:501792. doi: 10.1016/j.acuroe.2025.501792. PubMed
SIL S, Gayen S, Seal I, Das A, et al Exploring the chemotherapeutic potential of diosmetin ruthenium-p-cymene complex
in bladder cancer treatment through the regulation of the PI3K/beta-catenin/TJP1/AR
signaling pathway.
J Trace Elem Med Biol. 2025;90:127680. PubMed Abstract available
HSIAO CH, Lin YW, Liu CH, Chen YT, et al Nano-orchestrated magnetotactic-like navigation for electromagnetic theranostics
and immune enhancement via photoautotrophic oxygenation, mild hyperthermia, and
ferroptosis.
J Nanobiotechnology. 2025;23:442. PubMed Abstract available
ZHANG L, Zhang L, Gao S, Shi X, et al Galphai3: a crucial biomarker and therapeutic target in bladder cancer.
NPJ Precis Oncol. 2025;9:181. PubMed Abstract available
ENGELMANN SU, Pickl C, Haas M, Kasparbauer F, et al Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its
Origin.
Clin Genitourin Cancer. 2025 May 20:102378. doi: 10.1016/j.clgc.2025.102378. PubMed Abstract available
SCILIPOTI P, Moschini M, Zaurito P, Longoni M, et al Prognostic Implications of Patients With Clinically Node Positive Bladder Cancer
Undergoing Radical Cystectomy.
Clin Genitourin Cancer. 2025 May 17:102377. doi: 10.1016/j.clgc.2025.102377. PubMed Abstract available
CORMIO A, d'Altilia N, Calo B, Falagario UG, et al Stapled W-shaped (Hautmann) Orthotopic Ileal Neobladder. Functional Results and
Complications over a 13-year Period.
Eur Urol Focus. 2025;11:165-171. PubMed Abstract available
FERNANDEZ CARRASCO M, Sanchez Moreno S, Iglesias Asenjo E Recurrence of urothelial carcinoma. An unusual cause of upper gastrointestinal
bleeding.
Rev Esp Enferm Dig. 2025;117:346-347. PubMed Abstract available
REN H, Zou L, Jiang L, Zhang P, et al Prognostic role of circRNAs and RNA methylation enzymes in bladder cancer: A
systematic review and meta-analysis of Chinese studies.
Urol Oncol. 2025 Jun 26:S1078-1439(25)00218. PubMed Abstract available
MCELREE IM, Steinberg RL, Hougen HY, Mott SL, et al Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage
Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2025 Jun 26:S2405-4569(25)00152. PubMed Abstract available
SU W, Lai H, Tang X, Zhou Q, et al [Apelin promotes proliferation, migration, and angiogenesis in bladder cancer by
activating the FGF2/FGFR1 pathway].
Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:1289-1296. PubMed Abstract available
TASAKI Y, Nagai T, Naiki T, Noda Y, et al Effect of Pembrolizumab on Lymph Node Dissection in Patients Who Experienced
Bladder Cancer Recurrence Following Radical Cystectomy.
In Vivo. 2025;39:2196-2208. PubMed Abstract available
MIYAKE M, Yonemoto N, Togo K, Xu L, et al Deep Learning Model for Natural Language to Assess Effectiveness of Patients With
Non-Muscle Invasive Bladder Cancer Receiving Intravesical Bacillus
Calmette-Guerin Therapy.
JCO Clin Cancer Inform. 2025;9:e2400249. PubMed Abstract available
YE J, Xie Y, Ran B, Han P, et al Corrigendum: Prognostic impact of nutritional indicators based on Lasso-Cox
regression for non-muscle-invasive bladder cancer.
Front Nutr. 2025;12:1630197. PubMed Abstract available
YU H, Dong Y, Zou GC, Yang YJ, et al Exploring the molecular mechanism of Xiao Ji (Cirsium setosum) in treating
bladder cancer using network pharmacology and molecular docking.
Asian Biomed (Res Rev News). 2025;19:94-105. PubMed Abstract available
WARLI SM, Sihombing B, Kadar DD, Siregar GP, et al Comparison of long-term survival for muscle-invasive bladder cancer patients who
underwent bladder preservation therapy and radical cystectomy: A systematic
review and meta-analysis.
Urologia. 2025 Jun 26:3915603251347444. doi: 10.1177/03915603251347444. PubMed Abstract available
HUCK C, Achard V, Efstathiou J, Damme JV, et al Radiation Therapy in the Management of Muscle-invasive Bladder Cancer with
Carcinoma in Situ: Still a No Go?
Eur Urol Oncol. 2025 Jun 25:S2588-9311(25)00173. PubMed Abstract available
LIAO CH, Chang WS, Shih HY, Wang YC, et al Contribution of MRE11, RAD50, and NBS1 Genotypes to Bladder Cancer
Susceptibility.
Cancer Genomics Proteomics. 2025;22:575-591. PubMed Abstract available
OHTA T, Okamoto K, Inai H, Takayama T, et al Morphological changes in the muscle layer associated with invasion of bladder
cancer.
Clin Radiol. 2025;87:106973. PubMed Abstract available
MALUF FC, de Oliveira CSKS, Ziegelmann PK Survival According to Source of Treatment Funding in Bladder Cancer: Analysis of
a Large Public Database From Sao Paulo, Brazil.
JCO Glob Oncol. 2025;11:e2400648. PubMed Abstract available
POMARES-MILLAN H, Koutros S, Baris D, Schwenn M, et al Lifetime Water Arsenic, Genetic Susceptibility, And Bladder Cancer In The New
England Bladder Cancer Study.
JNCI Cancer Spectr. 2025 Jun 16:pkaf064. doi: 10.1093. PubMed Abstract available
CAI Z, Xie Y, Li L, Zheng Y, et al TET3 facilitates bladder cancer progression through targeted modulation of
stemness pathways.
Med Oncol. 2025;42:284. PubMed Abstract available
SOUIDEN L, Tu LM, Bordeleau M, Laberge G, et al Prevalence and predictive factors of complicated urinary tract infections post
bladder and prostate transurethral resections.
World J Urol. 2025;43:398. PubMed Abstract available
JIAO Z, Liu X, Yuan X, Wang X, et al KIAA1429 and AlkB Homolog 5 Regulate Bladder Cancer Progression via
N(6)-Methyladenosine-Dependent Modulation of Sonic Hedgehog Signaling.
Mol Carcinog. 2025 Jun 26. doi: 10.1002/mc.70004. PubMed Abstract available
AVUDAIAPPAN AP, Prabhakar P, Baker H, Roy MK, et al Survival outcomes with pelvic node dissection after partial cystectomy among
octogenarians with muscle-invasive bladder cancer.
Can J Urol. 2025;32:137-143. PubMed Abstract available
YANG Y, Wang Y, Zheng Z, Zhang H, et al Knockdown of PLK1 suppresses malignant phenotypes and tumor growth in bladder
cancer via activating Hippo pathway.
Gen Physiol Biophys. 2025;44:259-274. PubMed Abstract available
GANGULY A, Halder A, Healy K, Daugherty S, et al Metabolic Reprogramming of Urothelial Carcinoma-A Theragnostic Target for
Betulinic Acid.
Int J Mol Sci. 2025;26:5598. PubMed Abstract available
KABALAN Y, Matulewicz K, Tylkowski B, Wozniak-Budych M, et al Investigation of Anti-Cancer Properties of Nano-Encapsulated Ciprofloxacin Using
3D Cancer Cell Spheroids as Tumour Models.
Int J Mol Sci. 2025;26:5530. PubMed Abstract available
NDUKWE E, Lotan P, Risk M, Koehne EL, et al Statins Are Not Associated with Improved Bladder Cancer Outcomes in Patients with
Early-Stage Bladder Cancer Treated with BCG Immunotherapy.
Cancers (Basel). 2025;17:2027. PubMed Abstract available
KATSIMPERIS S, Tzelves L, Feretzakis G, Bellos T, et al Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: Implications for
Prognosis and Treatment Personalization.
Cancers (Basel). 2025;17:1908. PubMed Abstract available
HORI N, Matsumoto M, Miyamoto K, Mizuno K, et al Laparoscopic Colectomy for Sigmoid Colon Cancer in a Patient With a History of
Radical Cystectomy and Ileal Conduit Urinary Diversion.
Asian J Endosc Surg. 2025;18:e70108. PubMed Abstract available
GUNEY B, Alomari O, Mokresh ME, Eyvazova H, et al The role of preoperative and postoperative exercise in enhancing quality of life
following cystectomy for bladder cancer: a systematic review and meta-analysis.
Support Care Cancer. 2025;33:629. PubMed Abstract available
HUANG H, Feng S, Liu Y The role and mechanism of human papillomavirus in urinary system tumors.
J Int Med Res. 2025;53:3000605251348233. PubMed Abstract available
LIU J, Shi Z, Li Y, Ma J, et al High-resolution transcriptome atlas of bladder cancer highlights the functional
myeloid subsets in modulating immune microenvironment.
EBioMedicine. 2025;117:105801. PubMed Abstract available
HOSSEINI SA, Farasati M Apigenin and treating bladder cancer: a mini-review of the current literature.
Nat Prod Res. 2025 Jun 25:1-6. doi: 10.1080/14786419.2025.2524610. PubMed Abstract available
MIYAKE M, Owari T, Iida K, Onishi S, et al Clinical relevance of Nectin-4 downregulation and biological changes caused by
cytotoxic chemotherapy in bladder cancer.
Cancer Chemother Pharmacol. 2025;95:62. PubMed Abstract available
LI W, Shangguan W, Huang W, Zhao J, et al Gut Parabacteroides distasonis-derived Indole-3-Acetic Acid Promotes Phospholipid
Remodeling and Enhances Ferroptosis Sensitivity via the AhR-FASN Axis in Bladder
Cancer.
Adv Sci (Weinh). 2025 Jun 25:e04688. doi: 10.1002/advs.202504688. PubMed Abstract available
WONG R, Borgert B, Matulewicz RS, Goldstein AO, et al Analyzing Smoking Challenges in Bladder Cancer Patients From an Online Forum: A
Contemporary Qualitative Study of Peer Support and Cessation Motivators.
Tob Use Insights. 2025;18:1179173X251355758. PubMed Abstract available
SIREGAR GP, Parwati I, Safriadi F, Tjahjodjati T, et al Assessing the Impact of VEGF -2578C>A (rs699947) and -7C>T (rs2010963)
Polymorphisms on Bladder Cancer Susceptibility: A Pilot Study.
World J Oncol. 2025;16:295-298. PubMed Abstract available
NAH S, Choi S, Kim WB, Han S, et al Iatrogenic Bladder Rupture After Insertion of a Urinary Catheter in a Patient
With Bladder Cancer: A Case Report.
J Emerg Nurs. 2025 Jun 23:S0099-1767(25)00172-2. doi: 10.1016/j.jen.2025. PubMed Abstract available
ANDREASSON A, Andersson J, Larsson H, Ekerhult T, et al A prospective randomised pilot study evaluating the safety of the novel
LubriShield Foley catheter: a permanently coated indwelling urinary catheter.
Scand J Urol. 2025;60:124-129. PubMed Abstract available
BLICHERT-REFSGAARD L, Lindgren MS, Sundelin MO, Graugaard-Jensen C, et al Use of Photodynamic diagnosis (PDD) at primary TURB: Potential influence on
recurrence and progression rates in NMIBC: a registry-based study using a country
cohort.
Scand J Urol. 2025;60:115-123. PubMed Abstract available
XU W, Liang T, Fang H, Fu L, et al Single-Cell RNA Sequencing Identifies MMP11(+) Cancer-Associated Fibroblasts as
Drivers of Angiogenesis and Bladder Cancer Progression.
Adv Sci (Weinh). 2025 Jun 24:e02774. doi: 10.1002/advs.202502774. PubMed Abstract available
LI KP, Wang CY, Yang L Response to Letter: Reply Letter to Dr. Kumar et al. on: Enhanced Artificial
Intelligence in Bladder Cancer Management: A Comparative Analysis and
Optimization Study of Multiple Large Language Models.
J Endourol. 2025 Jun 24. doi: 10.1089/end.2025.0426. PubMed
ABUSAL F, Alawadi A, Akpala A, Obeidat S, et al Long-Term Complications and Quality of Life After Urinary Diversion for Bladder
Cancer: A Systematic Review and Meta-Analysis.
Cureus. 2025;17:e84744. PubMed Abstract available
MEBROUKINE S, Klein C, Yacoub M, Capon G, et al Utility of restaging transurethral resection in patients with primary high-grade
Ta bladder cancer.
World J Urol. 2025;43:387. PubMed Abstract available
HE L, Liu P GSK343, an inhibitor of EZH2, prevents acquired cisplatin resistance in bladder
cancer.
Mol Genet Genomics. 2025;300:63. PubMed Abstract available
ALI B, Franck B, Rusch E Microbiome And Immunotherapy In Bladder Cancer: The Missing Link.
Fr J Urol. 2025 Jun 21:102922. doi: 10.1016/j.fjurol.2025.102922. PubMed Abstract available
VETSCH T, Huber M, Wuethrich PY, Furrer MA, et al Preoperative prediction of severe short-term complications in patients with
bladder cancer undergoing radical cystectomy.
Surg Oncol. 2025;61:102253. PubMed Abstract available
YE H, Yu L, Chen Y Ureteral calculus complicated by bladder malakoplakia: A case report.
Medicine (Baltimore). 2025;104:e42926. PubMed Abstract available
JOYCE DD, Wymer KM, Graves JA, Boorjian SA, et al Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive
Bladder Cancer.
JAMA Netw Open. 2025;8:e2517056. PubMed Abstract available
DAI C, Li Q, Wang L, Zhang J, et al LncRNA TRPM2-AS promotes cell proliferation, migration, and invasion by
regulating the miR-195-5p/COP1 axis in bladder cancer.
Naunyn Schmiedebergs Arch Pharmacol. 2025. PubMed Abstract available
SUN M, Zhang Q, He Z, Luo Y, et al Integrated Multiomics Analysis and Machine Learning Approaches in Bladder Cancer:
Unveiling the Impact of Immunogenic Cell Death and Its Key Gene SLC2A3 on
Prognosis and Personalized Treatment Strategies.
ACS Omega. 2025;10:24655-24674. PubMed Abstract available
YANG X, Cai L, Xin Y, Chen X, et al Potential of Urinary Mutation and Methylation Biomarkers in Selecting Candidates
for Repeat Transurethral Resection of Bladder Tumor in Non-muscle-invasive
Bladder Cancer: A Prospective Multicenter Study.
Eur Urol Open Sci. 2025;77:49-57. PubMed Abstract available
ROBESTI D, Micheli F, Rai SN, Fallara G, et al Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The
neglected impact of informative censoring. A systematic review and meta-analysis.
Crit Rev Oncol Hematol. 2025;214:104815. PubMed Abstract available
RAFIEI F, Masoumi N, Faghihloo E Investigating the expression of HERV-K env, np9, gag, and rec in bladder cancers.
Infect Agent Cancer. 2025;20:41. PubMed Abstract available
REMMELINK MJ, Awadly NE, Arbeel-Weening B, Nadorp S, et al Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and
development of new hydronephrosis.
Radiat Oncol. 2025;20:104. PubMed Abstract available
DA CUNHA AGOSTINI L, da Silva GN Type 2 Diabetes Mellitus and bladder cancer: A narrative review on associated
signaling pathways.
Mol Aspects Med. 2025;104:101381. PubMed Abstract available
XIONG W, Liu Y, Yang H, Zhang B, et al Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and
potentiates antitumor immunity in bladder cancer.
Int Immunopharmacol. 2025;162:115057. PubMed Abstract available
HARPER S, Remer EM, Almassi N Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment
Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers.
Curr Urol Rep. 2025;26:51. PubMed Abstract available
ZHANG Y, Yang E, Zhang X, Zhang Z, et al Autophagy-related biological targets and network mechanisms of juglone against
bladder cancer.
J Cancer Res Clin Oncol. 2025;151:194. PubMed Abstract available
GUO Y, Lin Z, Zhang W, Chen H, et al Comprehensive multi-omics analysis of nucleotide metabolism: elucidating the role
and prognostic significance of UCK2 in bladder cancer.
Funct Integr Genomics. 2025;25:133. PubMed Abstract available
PAN Q, Zou C, Lin Z, Tang H, et al TFAP2C Drives Cisplatin Resistance in Bladder Cancer by Upregulating YAP and
Activating beta-Catenin Signaling.
J Biol Chem. 2025 Jun 18:110387. doi: 10.1016/j.jbc.2025.110387. PubMed Abstract available
SAXENA M, Anker JF, Kodysh J, O'Donnell T, et al Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a
phase 1 trial.
Nat Cancer. 2025;6:988-999. PubMed Abstract available
LIN CH, Hung PH, Chang CH, Chang H, et al LINE-1 DNA methylation mediates smoking-related risk in site-specific urothelial
carcinoma: a Taiwan case-control study.
Arch Toxicol. 2025;99:3035-3046. PubMed Abstract available
QOSJA N, Spaulding AC, Colibaseanu DT, Zganjar AJ, et al Market-Level Features May Influence a Hospital's Decision to Perform Robotic
Radical Cystectomy in Florida.
Urol Pract. 2025;12:391-400. PubMed Abstract available
FURIHATA K, Kurabayashi A, Iwashita W, Wada N, et al Poorly Differentiated Carcinoma with only Clear Glandular Differentiation Arising
from the Bladder Trigone: A Case of Adenocarcinoma or Urothelial Carcinoma?
Keio J Med. 2025;74:113-118. PubMed Abstract available
KRISHNAN A, Maitre P, Kashid S, Pansande N, et al Online Adaptive Radiation Therapy for Bladder Preservation: Transitioning to
Hypofractionation.
Int J Radiat Oncol Biol Phys. 2025;122:995-1001. PubMed Abstract available
VILLARREAL-GONZALEZ R, Trevino-Morales AK, Cadenas-Garcia D, Lopez-Galindo A, et al Management and desensitization to Avelumab in anaphylaxis and metastatic
urothelial carcinoma: A case report.
J Oncol Pharm Pract. 2025;31:839-841. PubMed Abstract available
CHAACHOU-CHARRADI A, Bague S, Medina CM, Lavernia J, et al Primary Visceral Ewing Sarcoma (Gastric and Bladder) with KIT Expression: A
Report of Two Patients and a Differential Diagnostic Approach.
Int J Surg Pathol. 2025;33:1299-1316. PubMed Abstract available
LUO C, Li S, Han Y, Ling J, et al Noninvasive identification of HER2 status by integrating multiparametric
MRI-based radiomics model with the vesical imaging-reporting and data system
(VI-RADS) score in bladder urothelial carcinoma.
Abdom Radiol (NY). 2025;50:3126-3136. PubMed Abstract available
LI L, Jiang L, Yang K, Luo B, et al A novel artificial intelligence segmentation model for early diagnosis of bladder
tumors.
Abdom Radiol (NY). 2025;50:3092-3099. PubMed Abstract available
NAGANATANAHALLI M, Afshari Mirak S, Ojili V, Ramaiya NH, et al Intravesical BCG therapy: implications for radiologists in abdominal imaging
follow-up.
Abdom Radiol (NY). 2025;50:3249-3261. PubMed Abstract available
WANG L, Wali M, Sun Y Primary melanoma of the urinary tract: a clinicopathological study of cases and
literature review.
J Clin Pathol. 2025;78:443-448. PubMed Abstract available
MATSUO T, Miyata Y, Harada J, Itoh I, et al Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and
Metastatic Urothelial Cancer.
Anticancer Res. 2025;45:2563-2573. PubMed Abstract available
ONISHI T, Sekito S, Shibahara T, Yabana T, et al Randomized Study of Short-time Continuous Saline Irrigation After Transurethral
Resection in Non-muscle Invasive Bladder Cancer.
Anticancer Res. 2025;45:2653-2660. PubMed Abstract available
KWONG JCC, Pace K, Al-Daqqaq Z, Chelliahpillai Y, et al Impact of concomitant carcinoma in situ distribution on non-muscle-invasive
bladder cancer progression risk.
BJU Int. 2025 May 26. doi: 10.1111/bju.16793. PubMed Abstract available
TEMPO J, Felemban S, Qin KR, Perera M, et al Radical cystectomy mortality in older patients: a systematic review and
meta-analysis.
BJU Int. 2025;136:19-31. PubMed Abstract available
ERAKY A, Ben-David R, Hug B, Kolanukuduru KP, et al Bladder neck involvement in non-muscle-invasive bladder cancer: risk implications
and outcomes of BCG vs gemcitabine/docetaxel.
BJU Int. 2025 Jun 15. doi: 10.1111/bju.16827. PubMed Abstract available
BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al What spatial omics is teaching us about field cancerisation in prostate and
bladder cancer.
BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830. PubMed Abstract available
FERRO M, Catellani M, Bianchi R, Fallara G, et al Enhanced prognostic value of four-tier hybrid grading system in Ta
non-muscle-invasive bladder cancer.
BJU Int. 2025 Jun 25. doi: 10.1111/bju.16828. PubMed Abstract available
TATEO V, de Jong JJ, Cigliola A, Maiorano BA, et al Impact of molecular androgen and estrogen response scores on outcomes following
neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
Clin Cancer Res. 2025 Jun 20. doi: 10.1158/1078-0432.CCR-24-4312. PubMed Abstract available
BABAEVSKAYA D, Morozov A, Fridman E, Tsoy L, et al En bloc resection of large bladder tumor: is it feasible and reasonable?
Curr Opin Urol. 2025;35:385-389. PubMed Abstract available
SULEJA A, Laukhtina E, Cormio A, Miszczyk M, et al Adjuvant radiotherapy following radical cystectomy in patients with
muscle-invasive bladder cancer: a narrative review.
Curr Opin Urol. 2025 Jun 23. doi: 10.1097/MOU.0000000000001310. PubMed Abstract available
FU MZ, Ghodoussipour S, Packiam VT Re: Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer:
Results from Phase II Protocol NRG Oncology/RTOG 0926.
Eur Urol. 2025 Jun 10:S0302-2838(25)00326-4. doi: 10.1016/j.eururo.2025. PubMed
RUI X, Xu X, Dai B Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder
Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled
DaBlaCa-15 Trial. Eur
Eur Urol. 2025 Jun 7:S0302-2838(25)00339-2. doi: 10.1016/j.eururo.2025. PubMed
CHANG SS, Launer B, Narayan V, Patil D, et al Computational Histology Artificial Intelligence (CHAI) Enhances Risk
Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a
Multicenter Cohort: Comparison to Current European Association of Urology and
American Urological Association
Eur Urol. 2025 Jun 12:S0302-2838(25)00338-0. doi: 10.1016/j.eururo.2025. PubMed
DREYER T, Jensen JB Reply to Xin Rui, Xiaoming Xu, and Bo Dai's Letter to the Editor re: Thomas
Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer
Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive Bladder Canc
Eur Urol. 2025 Jun 24:S0302-2838(25)00348-3. doi: 10.1016/j.eururo.2025. PubMed
YAMAMOTO S, Fukuhara H, Kuroiwa H, Shigehisa R, et al Preoperative Pyuria as a Predictor of False-Positive Rates in the Photodynamic
Diagnosis of Nonmuscle-Invasive Bladder Cancer Using Oral 5-Aminolevulinic Acid.
Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70134. PubMed Abstract available
FUKIAGE Y, Muramoto A, Terada N, Kobayashi M, et al Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy
of Bacillus Calmette-Guerin Therapy for Bladder Carcinoma In Situ.
Int J Urol. 2025;32:737-746. PubMed Abstract available
XU S, Shi H, Yu F, Lu M, et al Outcomes of Second Resection Following Conventional Initial Transurethral
Resection of Bladder Tumors.
Int J Urol. 2025;32:720-726. PubMed Abstract available
MORGANS AK, Mucha L, Quicquaro C, Shih V, et al Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients
Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to
Receiving Enfortumab Vedotin: A Real-World Evidence Study.
Int J Urol. 2025;32:650-657. PubMed Abstract available
OZAKI K, Yamamoto H, Sekine Y, Horiguchi H, et al Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or
Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World
Multicenter Study.
Int J Urol. 2025;32:679-685. PubMed Abstract available
SOLTANI S, Rahimi HR, Mottaghi M, Tavakkoli M, et al Comparison of microRNA-21 expression in bladder cancer tumor with
normal-appearing adjacent tissue and healthy controls.
Int Urol Nephrol. 2025 Jun 13. doi: 10.1007/s11255-025-04581. PubMed Abstract available
LI Y, Sun X, Wang Y, Ma B, et al Prognostic factors in T1 high-grade urothelial carcinoma of the bladder with
lymphovascular invasion: a retrospective cohort study.
Int Urol Nephrol. 2025;57:2099-2105. PubMed Abstract available
GUBBIOTTI M, Rubilotta E, Bacchiani M, Cocci A, et al Intravesical administration of highly concentrated hyaluronic acid and
chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus
Calmette-Guerin (BCG) immunotherapy.
Int Urol Nephrol. 2025;57:2033-2039. PubMed Abstract available
KOTI M, Michaud E, Siemens DR Non-modifiable drivers of BCG response: Considerations of age, sex and chronic
inflammation for the management of non-muscle invasive bladder cancer.
J Urol. 2025 Jun 10:101097JU0000000000004632. doi: 10.1097/JU.0000000000004632. PubMed
MOYER JA, Durant AM, Nguyen MV, Mi L, et al Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During
Intravesical Administration of Nadofaragene Firadenovec for BCG-Unresponsive
Non-Muscle-Invasive Bladder Cancer.
J Urol. 2025 Jun 26:101097JU0000000000004658. doi: 10.1097/JU.0000000000004658. PubMed Abstract available
WEI X, Wang B, Yang Y, Fang Z, et al Crosstalk between SUMOylation and ubiquitination controls the stability of
transcription factor zinc finger protein 24: a novel antitumor mechanism in
bladder cancer.
Oncogene. 2025 May 28. doi: 10.1038/s41388-025-03450. PubMed Abstract available
ZHANG B, Dong G, Guo X, Li H, et al SFXN1 promotes bladder cancer metastasis by restraining PINK1-dependent
mitophagy.
Oncogene. 2025 Jun 4. doi: 10.1038/s41388-025-03460. PubMed Abstract available
WANG J, Ma R, Wu X, Yang W, et al Letter to the Editor on "A Comparison Between Intravesical Gemcitabine Plus
Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle
Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of
Oncological O
Urology. 2025 May 29:S0090-4295(25)00513-8. doi: 10.1016/j.urology.2025. PubMed
BELAND LE, Van Batavia JP, Mittal S, Kolon TF, et al Inflammatory Myofibroblastic Tumor of the Bladder in Childhood: A Three Case
Series.
Urology. 2025;200:e72-e75. PubMed Abstract available
THAKUR A, Kumar L Reply to editor comment on "A Comparison Between Intravesical Gemcitabine Plus
Docetaxel and Intravesical Bacillus Calmette-Guerin in the Treatment of Nonmuscle
Invasive Naive Urinary Bladder Cancer: A Systematic Review and Meta-analysis of
Oncologica
Urology. 2025 Jun 16:S0090-4295(25)00600-4. doi: 10.1016/j.urology.2025. PubMed
STARR S, Kazemi S, Moman P, Lin L, et al Disparities in Access to High Volume Centers for Muscle Invasive Bladder Cancer
and its Association With Treatment Patterns and Outcomes.
Urology. 2025 Jun 12:S0090-4295(25)00595-3. doi: 10.1016/j.urology.2025. PubMed Abstract available
XU M, Zhou J, Lv J, Zhang Y, et al Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer
analysis.
BMC Cancer. 2025;25:932. PubMed Abstract available
PAN Y, Shih HJ, Chuang SH, Chang CP, et al Effects of functional antioxidants on the expansion of gamma delta T-cells and
their cellular cytotoxicity against bladder cancer cells.
BMC Cancer. 2025;25:980. PubMed Abstract available
LI YH, Ou YC, Tung MC, Lin YS, et al Gender disparities in bladder cancer: A population-based study on life expectancy
and health spending in Asia.
PLoS One. 2025;20:e0323803. PubMed Abstract available
WANG B, Cao Z, Li Y, Zou H, et al Association between CYP17A1 rs743572 polymorphism and cancer risk: A
meta-analysis.
PLoS One. 2025;20:e0326843. PubMed Abstract available
